Generic Oracea Availability

Oracea is a brand name of doxycycline, approved by the FDA in the following formulation(s):

ORACEA (doxycycline - capsule; oral)

Has a generic version of Oracea been approved?

A generic version of Oracea has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Oracea and have been approved by the FDA:

doxycycline capsule; oral

  • Manufacturer: MYLAN
    Approval date: July 1, 2010
    Strength(s): 40MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oracea. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
    Patent 5,789,395
    Issued: August 4, 1998
    Inventor(s): Amin; Ashok R. & Abramson; Steven B. & Golub; Lorne M. & Ramamurthy; Nungavaram S. & McNamara; Thomas F. & Greenwald; Robert A. & Trachtman; Howard
    Assignee(s): The Research Foundation of State University of New York Hospital for Joint Diseases
    A method is disclosed for inhibiting endogenous production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo mammalian system. The method employs a tetracycline compound to inhibit production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase (iNOS). Preferably, the tetracycline compound has inhibitory activity for metalloproteinases. Also it is preferred that the tetracycline compound is provided to the mammalian system in an amount which has little or no antibacterial activity in the system. Accordingly, preferred tetracycline compounds are tetracycline compounds which have be modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by NO production mediated by iNOS, including, for example, inflammatory conditions.
    Patent expiration dates:
    • August 30, 2016
      ✓ 
      Patent use: TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
  • Method for inhibiting expression of inducible nitric oxide synthase with tetracycline
    Patent 5,919,775
    Issued: July 6, 1999
    Inventor(s): Amin; Ashok R. & Abramson; Steven B. & Golub; Lorne M. & Ramamurthy; Nungavaram S. & McNamara; Thomas F. & Greenwald; Robert A. & Trachtman; Howard
    Assignee(s): The Research Foundation of The State University of New York Hospital For Joint Diseases
    The invention is a method of inhibiting the production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo biological system. The method employs a tetracycline compound to inhibit the production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase (iNOS). Preferably, the tetracycline compound has inhibitory activity for metalloproteinases. Also it is preferred that the tetracycline compound is provided to the biological system in an amount which has little or no antibacterial activity in the system. Accordingly, preferred tetracycline compounds are tetracycline compounds which have be modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by NO production mediated by iNOS, including, for example, inflammatory conditions.
    Patent expiration dates:
    • August 30, 2016
      ✓ 
      Patent use: TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
  • Methods of treating acne
    Patent 7,211,267
    Issued: May 1, 2007
    Inventor(s): Ashley; Robert A.
    Assignee(s): CollaGenex Pharmaceuticals, Inc.
    A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.
    Patent expiration dates:
    • April 5, 2022
      ✓ 
      Patent use: TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
  • Methods of treating rosacea
    Patent 7,232,572
    Issued: June 19, 2007
    Inventor(s): Ashley; Robert A.
    Assignee(s): CollaGenex Pharmaceuticals, Inc.
    A method of treating rosacea in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat rosacea, but has substantially no antibiotic activity.
    Patent expiration dates:
    • April 5, 2022
      ✓ 
      Patent use: TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
  • Once daily formulations of tetracyclines
    Patent 7,749,532
    Issued: July 6, 2010
    Inventor(s): Chang; Rong-Kun & Raoufinia; Arash & Shah; Niraj
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Patent expiration dates:
    • December 19, 2027
      ✓ 
      Patent use: TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
      ✓ 
      Drug product
  • Once daily formulations of tetracyclines
    Patent 8,206,740
    Issued: June 26, 2012
    Inventor(s): Chang; Rong-Kun & Raoufinia; Arash & Shah; Niraj
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Patent expiration dates:
    • December 24, 2025
      ✓ 
      Patent use: TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
      ✓ 
      Drug product
  • Once daily formulations of tetracyclines
    Patent 8,394,405
    Issued: March 12, 2013
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Patent expiration dates:
    • December 24, 2025
      ✓ 
      Patent use: TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
      ✓ 
      Drug product
  • Once daily formulations of tetracyclines
    Patent 8,394,406
    Issued: March 12, 2013
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Patent expiration dates:
    • December 24, 2025
      ✓ 
      Patent use: TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
      ✓ 
      Drug product

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Advertisement
Close

Recommended

(web4)